CT PET SCANNING for GIT Malignancies
A clinician’s perspective

Damon Bizos
Head, Surgical Gastroenterology
Charlotte Maxeke Johannesburg Academic Hospital
Case presentation

• 54 year old with recent onset of dysphagia and loss of weight.
• Upper endoscopy: circumferential cancer from 36-40 cm=adenocarcinoma
• CT: 6 cm lesion with 2 suspicious nodes in lower mediastinum
• CT PET: no distant mets
Further management

• 6 weeks neoadjuvant chemo-radiotherapy
• Tolerated treatment reasonably well
• Dysphagia improved
• Upper endoscopy and biopsy
  – No signs of residual tumour
• CT-PET( whole body)
• Review of CT scan- no bony lesion seen

• PET hot spot-? Artefact

• Bone scan: negative
Axial T2 weighted MRI with fat suppression
Axial T2 weighted MRI with fat suppression 4 weeks later
Further management

• Diagnostic laparoscopy – no peritoneal disease
• Extra peritoneal exposure of L1 and bone biopsy:
  – Metastatic adenocarcinoma

• Patient counselled and sent for further chemotherapy
Lessons learned

• Believe your tests
• Use all tests at your disposal
• Consult widely
  – MDT
CT PET applications in oncology

• Tumour detection and differential diagnosis of benign and malignant tumours
• Tumour staging and prognostic stratification
• Evaluation of treatment response
• Restaging and detection of recurrent cancer
• Radiation treatment planning
• Development of new anticancer drugs

Astrid Langer  BMC Health services Research 2010, 10:283
CT PET and the gastroenterologist/surgeon

- GIT lesions picked up on CT PET for other indications
- CT PET for differentiating benign from malignant lesions pancreatic masses, Auto immune pancreatitis
- CT PET in
  - Initial staging
  - Response to treatment
  - Restaging after neoadjuvant treatment
  - Surveillance
- Economics
- Can we do CT and PET at same time and no need for dedicated CT
CT PET and the gastroenterologist/surgeon

- GIT lesions picked up on CT PET for other indications
- CT PET for differentiating benign from malignant lesions pancreatic masses, Auto immune pancreaticatitis
- CT PET in
  - Initial staging
  - Response to treatment
  - Restaging after neoadjuvant treatment
  - Surveillance
- Economics
- Can we do CT and PET at same time and no need for dedicated CT
Significance of Incidental 18F-FDG Accumulations in the Gastrointestinal Tract in PET/CT: Correlation with Endoscopic and Histopathologic Results
Ehab M. Kamel, Miriam Thumshirn; Kaspar Truninger, et al, University Hospital of Zurich, THE JOURNAL OF NUCLEAR MEDICINE • Vol. 45 • No. 11 • Nov. 2004

Conclusion:

• Although IDLs of the GIT on 18F-FDG PET/CT scans are found only in about 3% of cases,

• They are associated with a substantial risk of an underlying cancerous or precancerous lesion.

• Early identification of these occult lesions may have a major impact on the patients’ management and outcome.
Incidentally detected lesions (IDL)

- 98 (3%) of the 3,281 patients had an IDL of the GIT

- 69 patients had correlative endoscopic findings
  - 13 (19%) were harboring newly occurring cancers of the GIT
  - 12 had pre-existing aerodigestive tumors

- 29 (42%) patients had precancerous lesions
  - 27 advanced colonic adenomas
  - 1 Barrett’s esophagus,
  - and intestinal metaplasia of the gastric mucosa (*n* 1).

- 9 (13%) patients, PET/CT was false-positive, showing normal findings in subsequent endoscopic examinations.

- In 20 (28%) of 69 patients, PET/CT findings had a relevant impact on the clinical management.
CT PET and the gastroenterologist/surgeon

- GIT lesions picked up on CT PET for other indications
- CT PET for differentiating benign from malignant lesions pancreatic masses, Auto immune pancreatitis
- CT PET in
  - Initial staging
  - Response to treatment
  - Restaging after neoadjuvant treatment
  - Surveillance
- Economics
- Can we do CT and PET at same time and no need for dedicated CT
CT PET and the gastroenterologist/surgeon

- GIT lesions picked up on CT PET for other indications
- CT PET for differentiating benign from malignant lesions; pancreatic masses, Autoimmune pancreatitis
- CT PET in
  - Initial staging
  - Response to treatment
  - Restaging after neoadjuvant treatment
  - Surveillance
- Economics
- Can we do CT and PET at the same time and no need for dedicated CT
Surgery for GIT Malignancies

- Often high risk operations
  - Oesophagectomy
  - Whipple’s Procedure
  - Hepatectomy
  - Total gastrectomy and lymphadenectomy
  - Low anterior resections
Palliative surgery decreasing

- Better chemotherapy
- Better pain relief
- Stents for obstruction, perforation
- Bleeding: argon beam, embolization, radiotherapy

- No proven benefit in most cases of debulking surgery in GIT
  - colorectal?
ROLE OF CT PET

If CT PET shows increased uptake outside proposed radical resection,

AND if this is PROVEN to be distant spread

THEN

No point in performing the radical surgery
Why is it important to get pathological proof of metastatic disease?

- Artefacts
- Infection especially TB
- Second malignancy with a different prognosis
- Pathological proof often upstages and changes treatment substantially
If cost and availability no object

Diagnosis
Staging
CT PET for ultimate staging
Neoadjuvant therapy
CT PET to assess early response
CT PET 4-6 weeks after completion of neoadjuvant therapy
Surgery
GIT Applications of PET

**Oesophagus**

oesophagus; poor prognosis

- CT, MRI, Endo US - poor assessment of distant disease
- +/- 100% accuracy in detecting primary
  - Small T1 primaries may be missed
- Upgrades staging – 20% changed management
GIT Applications of PET

Oesophagus

• CT –PET poor for loco-regional staging

• Prognostic role??
  – Increased glucose uptake- worse prognosis??
  – Decreased SUV denotes better response to neoadjuvant CRT
  – Decreased SUV denotes good response to Chemo at 14 days
# Oesophageal Cancer

Table I. Representative studies regarding sensitivity of primary tumour and stage IV disease of FDG-PET in oesophagus carcinoma

<table>
<thead>
<tr>
<th>Author (Reference)</th>
<th>Patients (no.)</th>
<th>Primary tumour Sensitivity (%)</th>
<th>Stage IV disease</th>
<th>Sens. (%)</th>
<th>Spec. (%)</th>
<th>Acc. (%)</th>
<th>Sens. (%)</th>
<th>Spec. (%)</th>
<th>Acc. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Block (10)</td>
<td>58</td>
<td>97</td>
<td>CT</td>
<td>29</td>
<td>0</td>
<td>96*</td>
<td>78*</td>
<td>100</td>
<td>71*</td>
</tr>
<tr>
<td>Flanagan (11)</td>
<td>36</td>
<td>100</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kole (12)</td>
<td>26</td>
<td>96</td>
<td>PET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rankin (13)</td>
<td>25</td>
<td>100</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luketich (14)</td>
<td>91</td>
<td>97#</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flamen (15)</td>
<td>74</td>
<td>95</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skehan (16)</td>
<td>61</td>
<td>91</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim (17)</td>
<td>53</td>
<td>96</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kato (18)</td>
<td>32</td>
<td>78</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CT = computed tomography; PET = positron emission tomography; Sens. = sensitivity; Spec. = specificity; Acc. = Accuracy.

*Calculated data.

#Percentage of a subgroup.
# Oesophageal Cancer

Table 1. Representative studies regarding sensitivity of primary tumour and stage IV disease of FDG-PET in oesophagus carcinoma

<table>
<thead>
<tr>
<th>Author (Reference)</th>
<th>Patients (no.)</th>
<th>Primary tumour Sensitivity (%)</th>
<th>Stage IV disease</th>
<th>PET</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CT</td>
<td>PET</td>
<td></td>
</tr>
<tr>
<td>Block (10)</td>
<td>58</td>
<td>97</td>
<td>29</td>
<td>96*</td>
</tr>
<tr>
<td>Flanagan (11)</td>
<td>36</td>
<td>100</td>
<td>0</td>
<td>95*</td>
</tr>
<tr>
<td>Kole (12)</td>
<td>25</td>
<td>100</td>
<td>67*</td>
<td>95*</td>
</tr>
<tr>
<td>Rankin (13)</td>
<td>25</td>
<td>97</td>
<td>46</td>
<td>73</td>
</tr>
<tr>
<td>Luketich (14)</td>
<td>91</td>
<td>97</td>
<td>41</td>
<td>83</td>
</tr>
<tr>
<td>Flamen (15)</td>
<td>74</td>
<td>95</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skehan (16)</td>
<td>61</td>
<td>91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim (17)</td>
<td>53</td>
<td>96</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kato (18)</td>
<td>32</td>
<td>78</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CT = computed tomography; PET = positron emission tomography; Sens. = sensitivity; Spec. = specificity; Acc. = Accuracy.

*Calculated data.

#Percentage of a subgroup.
## Table I. Representative studies regarding sensitivity of primary tumour and stage IV disease of FDG-PET in oesophagus carcinoma

<table>
<thead>
<tr>
<th>Author (Reference)</th>
<th>Patients (no.)</th>
<th>Primary tumour Sensitivity (%)</th>
<th>Sens. (%)</th>
<th>Spec. (%)</th>
<th>Acc. (%)</th>
<th>Sens. (%)</th>
<th>Spec. (%)</th>
<th>Acc. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Block (10)</td>
<td>58</td>
<td>97</td>
<td>29</td>
<td>96*</td>
<td>78*</td>
<td>100</td>
<td>100*</td>
<td>94*</td>
</tr>
<tr>
<td>Flanagan (11)</td>
<td>36</td>
<td>100</td>
<td>0</td>
<td>95*</td>
<td>88*</td>
<td>100</td>
<td>90*</td>
<td>92*</td>
</tr>
<tr>
<td>Kole (12)</td>
<td>26</td>
<td>96</td>
<td>67*</td>
<td>95*</td>
<td>88*</td>
<td>100</td>
<td>90*</td>
<td>92*</td>
</tr>
<tr>
<td>Rankin (13)</td>
<td>25</td>
<td>100</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luketich (14)</td>
<td>91</td>
<td>97#</td>
<td>46</td>
<td>73</td>
<td>63</td>
<td>69</td>
<td>93</td>
<td>84</td>
</tr>
<tr>
<td>Flamen (15)</td>
<td>74</td>
<td>95</td>
<td>41</td>
<td>83</td>
<td>64</td>
<td>74</td>
<td>90</td>
<td>82</td>
</tr>
<tr>
<td>Skehan (16)</td>
<td>61</td>
<td>91</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim (17)</td>
<td>53</td>
<td>96</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kato (18)</td>
<td>32</td>
<td>78</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CT = computed tomography; PET = positron emission tomography; Sens. = sensitivity; Spec. = specificity; Acc. = Accuracy.

*Calculated data.

#Percentage of a subgroup.
Predictors of complete pathological response after neo-adjuvant chemoradiotherapy in Oesophageal cancer?

- Endoscopy and biopsy
- Endoscopic Ultrasound
- CT- wall thickness
- CT -PET
GIT applications of PET
Colorectal carcinoma

Rising CEA after CRC resection

- Sensitivity 60-70%
- Specificity 84%
- CT misses 7% liver mets
- CT misses metastases to peritoneum, mesentery and LNs
- CT cannot differentiate tumor from surgical scarring
GIT applications of PET
Colorectal carcinoma

• Presumed isolated liver metastases
  – Normally referred for resection
  – May have occult metastases in over 30%
GIT applications of PET

Colorectal carcinoma

• CT PET for CRC
  – Sensitivity 97%
  – Specificity 76%

• CT PET in CRC to liver

• Sensitivity and specificity >97%
GIT applications of PET
Colorectal carcinoma

Influence in decision making

• Direct influence in MX in 59% (Kalff et al)
• Mx changed in 29-40% of CRC to liver

• ? Use for predicting prognosis or response to therapy
GIT applications of PET
Colorectal carcinoma: summary

• Rising CEA without a focus on conventional screening
• Differentiating fibrosis from LR recurrence
• Pre-op staging in potentially resectable recurrent CRC
• Staging of CRC (Primary) if CEA raised??
### Recurrent colorectal carcinoma

Table II. Adapted from a meta-analysis by Huebner et al. (27): sensitivity, specificity and change of management owing to FDG-PET in recurrent colorectal cancer

<table>
<thead>
<tr>
<th>Author (Reference no.)</th>
<th>Patients</th>
<th>Sensitivity ($n$)</th>
<th>Specificity</th>
<th>Change in management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beets (28)</td>
<td>35</td>
<td>96%</td>
<td>97%</td>
<td>40%</td>
</tr>
<tr>
<td>Schiepers (29)</td>
<td>76</td>
<td>95%</td>
<td>80%</td>
<td>25%</td>
</tr>
<tr>
<td>Vitola (30)</td>
<td>24</td>
<td>95%</td>
<td>67%</td>
<td>29%</td>
</tr>
<tr>
<td>Lai (31)</td>
<td>34</td>
<td>100%</td>
<td>83%</td>
<td>33%</td>
</tr>
<tr>
<td>Delbeke (32)</td>
<td>61</td>
<td>98%</td>
<td>80%</td>
<td></td>
</tr>
<tr>
<td>Keogan (33)</td>
<td>18</td>
<td>92%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogunbiyi (34)</td>
<td>47</td>
<td>90%</td>
<td>100%</td>
<td>44%</td>
</tr>
<tr>
<td>Ruhlmann (35)</td>
<td>59</td>
<td>100%</td>
<td>69%</td>
<td>31%</td>
</tr>
<tr>
<td>Flanagan (36)</td>
<td>22</td>
<td>100%</td>
<td>71%</td>
<td>20%</td>
</tr>
<tr>
<td>Valk (37)</td>
<td>115</td>
<td>95%</td>
<td>79%</td>
<td></td>
</tr>
<tr>
<td>Flamen (38)</td>
<td>103</td>
<td>94%</td>
<td>100%</td>
<td></td>
</tr>
</tbody>
</table>

FDG-PET = $2^{18}$F-fluoro-2-deoxy-D-glucose positron emission tomography.
GIT Applications of PET

Pancreatic carcinoma

• Main role to differentiate between “mass forming CP” and pancreatic cancer
  – Diabetes and inflammation a problem
• Can be used to look for hepatic mets
  – >1cm sens and spec > 95%
  – <1cm, sens 46%, spec 97%
• Prognostic role and monitoring therapy promising
• Differentiating Autoimmune pancreatitis from cancer?
### Pancreatic lesions: benign or malignant?

#### Table III. Sensitivity and specificity of FDG-PET for diagnosis of pancreatic carcinoma in patients with pancreatic lesions

<table>
<thead>
<tr>
<th>Author (Reference no.)</th>
<th>Patients (n)</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friess (56)</td>
<td>80</td>
<td>94%</td>
<td>88%</td>
</tr>
<tr>
<td>Inokuma (57)</td>
<td>46</td>
<td>94%</td>
<td>82%</td>
</tr>
<tr>
<td>Stollfuss (58)</td>
<td>73</td>
<td>95%</td>
<td>90%</td>
</tr>
<tr>
<td>Zimny (59)</td>
<td>106</td>
<td>85%</td>
<td>84%</td>
</tr>
<tr>
<td>Rose (60)</td>
<td>65</td>
<td>92%</td>
<td>65%</td>
</tr>
<tr>
<td>Frohlich (61)</td>
<td>168</td>
<td>68%</td>
<td>95%</td>
</tr>
<tr>
<td>Imdahl (62)</td>
<td>48</td>
<td>96%</td>
<td>100%</td>
</tr>
<tr>
<td>Diederichs (63)</td>
<td>304</td>
<td>81%</td>
<td>83%</td>
</tr>
<tr>
<td>Nakamoto (64)</td>
<td>47</td>
<td>96%</td>
<td>75%</td>
</tr>
<tr>
<td>Koyama (65)</td>
<td>86</td>
<td>82%</td>
<td>81%</td>
</tr>
<tr>
<td>Sperti (66)</td>
<td>56</td>
<td>94%</td>
<td>97%</td>
</tr>
<tr>
<td>Papos (67)</td>
<td>22</td>
<td>100%</td>
<td>88%</td>
</tr>
</tbody>
</table>

FDG-PET = 2-(\(^{18}\)F)-fluoro-2-deoxy-D-glucose positron emission tomography.
Surveillance

- Differentiating scar tissue from recurrent disease
  - Pelvic recurrence
  - Oesophageal cancer
  - Post Whipple’s procedure
CT PET and the gastroenterologist/surgeon

- GIT lesions picked up on CT PET for other indications
- CT PET for differentiating benign from malignant lesions pancreatic masses, Auto immune pancreatitis
- CT PET in
  - Initial staging
  - Response to treatment
  - Restaging after neoadjuvant treatment
  - Surveillance
- Economics
- Can we do CT and PET at same time and no need for dedicated CT
Cost effectiveness

Most studies of CT PET report

Diagnostic Accuracy

NOT

Improved patient outcomes
Cost effectiveness

Studies have been performed, some showing CT PET to be cost effective e.g. for presumed isolated liver mets in CRC

Such studies will need to be
- Scenario specific
- Country /region specific
- Alternative therapy specific
How much anatomical detail should we get from the CT component of a CT PET?

• Higher resolution CT scans may decrease number of additional CT needed but
• Need high resolution CT scanner
• Need expertise and proper protocols
• Radiation increased
• May not be needed for assessing treatment response
Competing technologies

- Endoscopic ultrasound
Competing Technologies

• MRI with contrasts, Tin
• Improved CT
• Diagnostic laparoscopy
• Staging laparoscopy
Figure 4: Miliary implants from a recurrent esophagogastric junction tumor. Metastatic disease was discernible only by laparoscopy.
Lessons learned

• CT PET changes decision making in 20-30 percent
• Need to confirm metastatic disease
• CT PET not good for locoregional spread
• CT PET not a good predictor of PCR
• Decreased use of diagnostic laparoscopy
Many surgeons personalise use of CT PET instead of using it in standardised algorithms

- Perceived COST
- Hassle factor of organising CT PET
- Improved anatomical imaging (CT, MRI, EUS)
- “routine cases”
- Doubt re accuracy???
- Lack of MDTs
Case 1

• 68 yr old female—previously well
• July 2004 – Adenocarcinoma of the distal oesophagus
• CT- Lesion extending to cardia with 1 cm coeliac node
• Decision- Chemoradiotherapy
  (Taxotere , infusional Cisplat and 5 FU +DXT)
Case 1 ctd

- Jan 2005 - rescope - no residual tumor
- Feb 2005 - UK
  - Endoscopic ultrasound (radial)
  - FDG PET with CT anatomical fusion
    - No lesions found
- March 2005 – 2 stage oesophagectomy
- Histology- Small Residual TX- no nodes
- DVT and PE 2 months later
Initial CT Chest
Initial CT - Pre CRT
Case 2

- 68 yr old hypertensive, RIH
- Sept 2004- referred with adenocarcinoma distal oesophagus
- CT: Large long (7cm) lesion
- Decision to give neo-adjuvant CRT
- Jan 2005 rescope: no malignancy seen
Case 2 (ctd)

- CT chest and upper abdomen
  - lesion smaller and no evidence of Mets
- CT PET in London
  - UPTAKE IN PELVIC bones!!!!
  - MRI: lesions in iliac bones (PSA normal)
    - biopsied - adenocarcinoma
Case 2 (ctd)

• Decision to give DXT to pelvis
• Incarcerated RIH and small bowel radiation enteritis
  – Emergency operation 17 March 2005
  – Prolonged hosp stay (ileus/enteritis)
• Palliative care